Familial chylomicronemia syndrome (FCS) is a rare genetic disorder that prevents your body from breaking down certain fats in the blood, causing triglyceride levels to soar well above 885 mg/dL, sometimes past 1,000 mg/dL. For context, normal triglycerides sit below 150 mg/dL. Once thought to affect roughly 1 in a million people, a large retrospective review published through the American Heart Association found the actual prevalence is closer to 13 in a million, about 13 times higher than older estimates suggested.
What Causes FCS
FCS is caused by mutations in genes responsible for producing or supporting an enzyme called lipoprotein lipase (LPL). This enzyme sits on the inner walls of small blood vessels in your muscles, heart, and fat tissue. Its job is to break apart triglycerides from the food you eat so your cells can absorb the fatty acids for energy. When LPL doesn’t work properly, fat-rich particles called chylomicrons build up in your bloodstream with nowhere to go.
About 95% of FCS cases trace back to mutations in the LPL gene itself. More than 220 different mutations have been identified in this gene alone. The remaining 5% involve mutations in four other genes that each play a supporting role in triglyceride processing: APOC2 (which activates LPL), APOA5 (which helps LPL bind to fat particles), GPIHBP1 (which anchors LPL to blood vessel walls), and LMF1 (which helps LPL fold into its correct shape). FCS is autosomal recessive, meaning you need to inherit a defective copy of one of these genes from both parents.
Symptoms and Physical Signs
FCS typically shows up in childhood or adolescence, though some people aren’t diagnosed until early adulthood. The hallmark symptom is recurrent, severe abdominal pain, which often turns out to be acute pancreatitis triggered by extreme triglyceride levels. Pancreatitis in FCS can be life-threatening and tends to happen repeatedly. About 8% of patients in one Canadian study had developed chronic pancreatitis from these repeated episodes, and 24% reported pancreatic pain as their most severe physical symptom.
One of the more visible signs is eruptive xanthomas: small, yellowish, dome-shaped bumps on the skin, typically 1 to 4 mm across. They appear most often on the backs of the arms, hands, and buttocks and are caused by fat-laden cells accumulating in the skin. These bumps show up in roughly 8.5% of patients with severely elevated triglycerides. Some develop an inflammatory red ring around them.
Another sign that doctors may catch during an eye exam is lipemia retinalis, a milky or pale appearance of the blood vessels in the retina caused by the sheer concentration of fat particles circulating in the blood. The blood itself can look visibly creamy or white when drawn into a tube.
The Less Obvious Burden
Beyond the acute crises, FCS carries a quieter daily toll that often goes unrecognized. In a study of Canadian FCS patients, 16% reported generalized abdominal pain as their most severe symptom, separate from full-blown pancreatitis episodes. Cognitive symptoms also appeared: 8% reported difficulty concentrating, and 3% each described brain fog and impaired judgment at their worst. These symptoms can be hard to connect to a fat metabolism disorder, which may partly explain why FCS is so frequently misdiagnosed or diagnosed late.
The dietary restrictions alone create significant psychological and social strain. Living with FCS means constant vigilance over every meal, difficulty eating at restaurants or social gatherings, and anxiety about triggering a pancreatitis episode. Many patients describe feeling isolated by a condition that most doctors have never encountered.
How FCS Is Diagnosed
FCS is suspected when fasting triglycerides consistently exceed 885 mg/dL across multiple blood draws, particularly when there’s a history of pancreatitis, symptoms began at a young age, and standard triglyceride-lowering medications don’t bring levels down. The lack of common secondary causes for high triglycerides, such as uncontrolled diabetes, heavy alcohol use, or certain medications, further raises suspicion.
A clinical scoring tool developed by Moulin and colleagues helps clinicians estimate the likelihood of FCS versus a more common lookalike called multifactorial chylomicronemia syndrome (MCS). The score weighs factors like whether triglycerides remain persistently above 885 mg/dL, whether they never drop below about 175 mg/dL despite treatment, the patient’s age when symptoms began, a history of pancreatitis, and the absence of secondary causes. Patients with FCS tend to have higher triglycerides at every stage compared to those with MCS.
Definitive diagnosis requires genetic testing. Modern panels screen at least five core genes: LPL, GPIHBP1, APOA5, LMF1, and APOC2. Some panels also include additional genes like APOE, GPD1, and CREB3L3. Confirmation comes from finding two pathogenic mutations (one from each parent) in one of these genes.
FCS Versus Multifactorial Chylomicronemia
The distinction between FCS and MCS matters because their management differs. MCS is far more common and results from a combination of genetic susceptibility and lifestyle or metabolic factors like obesity, poorly controlled diabetes, or alcohol intake. People with MCS generally respond to standard treatments: fibrates, omega-3 fatty acids, and addressing the underlying contributing conditions. Their triglyceride levels can often be brought under control.
FCS, by contrast, is driven entirely by the genetic defect. Standard lipid-lowering drugs have little to no effect because the fundamental enzyme needed to clear triglycerides is absent or nonfunctional. This treatment resistance is one of the defining clinical features that separates FCS from MCS and is built into the diagnostic scoring criteria.
Dietary Management
For most of FCS history, an extremely low-fat diet has been the only management strategy. Patients are advised to limit total dietary fat to roughly 10 to 20 grams per day, a fraction of the 44 to 78 grams typical in an average diet. This means avoiding most oils, butter, nuts, fatty meats, full-fat dairy, fried foods, and many processed products. Even with strict adherence, triglyceride levels in FCS commonly remain above 1,000 mg/dL.
Medium-chain triglycerides (MCTs), found in coconut oil and available as supplements, are sometimes used as an alternative fat source because they’re absorbed differently and don’t require LPL to be processed. Alcohol must be avoided entirely, as it further impairs triglyceride clearance.
New Treatment Options
In December 2024, the FDA approved olezarsen (brand name Tryngolza) as the first medication specifically for adults with FCS. It’s given as a subcutaneous injection once a month at a dose of 80 mg, alongside dietary fat restriction.
Olezarsen works by blocking production of a protein called apolipoprotein C-III, which normally slows down triglyceride clearance. By reducing this protein, the drug helps the body clear triglycerides through pathways that don’t depend on the broken LPL enzyme. In the phase 3 BALANCE trial of 66 FCS patients, those receiving the 80 mg dose saw their triglycerides drop by an average of 43.5% after six months compared to placebo. Earlier trials in patients with elevated triglycerides (not exclusively FCS) showed reductions of 57% to 61% at similar doses. These are meaningful drops for a population that previously had no effective medication.
The approval of olezarsen represents a significant shift for FCS patients, many of whom have spent decades managing their condition through diet alone while still facing repeated pancreatitis hospitalizations. It does not eliminate the need for dietary fat restriction but offers a meaningful additional layer of protection against dangerous triglyceride spikes.